natgillin/translations-raw huggingface dataset:
No disease-free survival (DFS) benefit was noticed in this subgroup of patients (hazard ratio = 1.16, 95 % CI [0.73, 1.83] for DCarbH (TCH) versus ACD (ACT); hazard ratio 0.97, 95 % CI [0.60, 1.55] for ACDH (ACTH) versus ACD).
V preživetju brez bolezni v tej podskupini ni bilo opaziti koristi (razmerje ogroženosti = 1,16; 95-% IZ [0,73; 1,83] za DCarbH (TCH) v primerjavi z AC  D (AC  T); razmerje ogroženosti 0,97; 95-% IZ [0,60; 1,55] za AC  DH (AC  TH) v primerjavi z AC  D).
No distinct correlation between the maintenance opioid dose and Instanyl doses have been established, however in the second pivotal study patients with low maintenance opioid dose tended to achieve effective pain relief with a correspondingly lower strength of Instanyl compared to patients taking higher levels of maintenance opioid dose.
Med vzdrževalnim odmerkom opioidov in odmerki zdravila Instanyl niso ugotovili izrazite soodvisnosti, so pa v drugi ključni študiji bolniki na nižjih vzdrževalnih odmerkih opioidov dosegali zadovoljivo lajšanje bolečine z ustrezno nižjimi jakostmi zdravila Instanyl v primerjavi z bolniki na višjih vzdrževalnih odmerkih opioidov.
No dosage adjustment for needed for either product
za nobeno od zdravil.
No dosage adjustment in elderly patients is necessary.
Pri starostnikih ni potrebna prilagoditev odmerka.
No dosage adjustment is considered necessary in patients with hepatic impairment (see section 5.2).
Bolnikom z okvaro jeter odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dosage adjustment is considered necessary.
Prilagoditev odmerka ni potrebna.
No dosage adjustment is necessary based on race.
Odmerka linagliptina ni treba prilagajati različnim rasam.
No dosage adjustment is necessary for HCV patients of East Asian ancestry or patients with mild hepatic impairment (see section 5.2).
Pri HCV bolnikih vzhodnoazijskega porekla ali bolnikih z blago okvaro jeter prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
No dosage adjustment is necessary for patients with hepatic impairment (see section 5.2).
Bolnikom z okvaro jeter odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dosage adjustment is necessary for patients with mild or moderate hepatic impairment (Child-Pugh score 5-8).
Pri bolnikih z blago ali zmerno okvaro jeter (stopnje 5-8 po lestvici Child-Pugh) prilagoditev odmerka ni potrebna.
No dosage adjustment is necessary for patients with mild or moderate renal dysfunction (creatinine clearance 30 to 80 ml/min).
Pri bolnicah z blago do zmerno okvarjenim delovanjem ledvic (očistek kreatinina 30 do 80 ml/min) odmerka ni treba prilagajati.
No dosage adjustment is necessary for patients with mild renal impairment (CLcr ≥50 and <80 mL/min).
Pri bolnikih z blago ledvično okvaro (CLcr ≥ 50 in < 80 ml/min) prilagajanje odmerkov ni potrebno.
No dosage adjustment is necessary if methadone is co- administered with REYATAZ and ritonavir.
Pri sočasni uporabi metadona, zdravila REYATAZ in ritonavirja odmerkov ni treba prilagajati.
No dosage adjustment is necessary if methadone is co- administered with REYATAZ.
Pri sočasni uporabi metadona z zdravilom REYATAZ odmerkov ni treba prilagajati.
No dosage adjustment is necessary if methadone is co-administered with EVOTAZ.
Pri sočasni uporabi metadona in zdravila EVOTAZ odmerkov ni treba prilagajati
No dosage adjustment is necessary if you have a mildly or moderately impaired kidney function.
Pri blagi ali zmerni okvari ledvic odmerka ni treba prilagajati.
No dosage adjustment is necessary in elderly patients (see section 5.2).
Pri starejših bolnikih prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
No dosage adjustment is necessary in patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter odmerka ni potrebno prilagajati (glejte poglavje 5.2).
No dosage adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 – 80 ml/min).
Pri bolnikih z blago okvaro ledvic (očistek kreatinina 50-80 ml/min) ni potrebno prilagajati.
No dosage adjustment is necessary inolder people.
Starejšim bolnikom odmerka ni treba prilagoditi.
No dosage adjustment is necessary.
Odmerka ni treba prilagoditi.
No dosage adjustment is needed in patients over the age of 65 years.
Pri bolnikih, starejših od 65 let, ni potrebno prilagoditi odmerka.
No dosage adjustment is recommended in patients with impaired hepatic function (see section 5.2).
Pri bolnikih z okvaro jetrne funkcije prilagoditve odmerka posebej ne priporočamo (glejte poglavje 5.2).
No dosage adjustment is required based on age (see section 5.2).
Prilagajanje odmerka glede na starost ni potrebno (glejte poglavje 5.2).
No dosage adjustment is required for female patients as compared to male patients (see section 5.2).
Pri bolnicah v primerjavi z bolniki odmerka ni treba prilagajati (glejte poglavje 5.2).
No dosage adjustment is required for patients with mild renal impairment.
Bolnikom z blago okvaro ledvic odmerka ni potrebno prilagoditi.
No dosage adjustment is required for patients with renal impairment (see section 5.2).
Pri bolnikih z ledvično okvaro odmerka ni treba prilagajati (glejte poglavje 5.2).
No dosage adjustment is required for patients with renal impairment (see section 5.2).
Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati (glejte poglavje 5.2).
No dosage adjustment is required for patients ≥ 65 years of age (see section 5.2).
Prilagajanje odmerka pri starejših bolnikih, starih ≥ 65 let, ni potrebno (glejte poglavje 5.2).
No dosage adjustment is required for the elderly with creatinine clearance values > 50 ml/min (see section 5.2).
Starejšim z očistkom kreatinina > 50 ml/min odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dosage adjustment is required in elderly patients (see section 5.2).
Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dosage adjustment is required in elderly patients based on age alone.
Pri starejših bolnikih odmerka ni treba prilagajati zgolj zaradi starosti.
No dosage adjustment is required in patients over 65 years.
Bolnikom, starejšim od 65 let, odmerka ni treba prilagoditi.
No dosage adjustment is required in patients with hepatic impairment (see section 5.2).
Bolnikom z okvaro jeter odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dosage adjustment is required in patients with hepatic impairment.
Pri bolnikih z okvarjenim delovanjem jeter prilagoditev odmerka ni potrebna.
No dosage adjustment is required in patients with mild hepatic impairment (see section 5.2).
Bolnikom z blago okvaro jeter odmerka ni treba prilagoditi.
No dosage adjustment is required in patients with mild or moderate renal impairment.
Pri bolnikih z blago ali zmerno okvarjenim delovanjem ledvic prilagoditev odmerka ni potrebna.
No dosage adjustment is required in patients with mild, moderate or severe (CrCl <30 mL/min, not on dialysis) renal impairment.
Pri bolnikih z blago, zmerno ali hudo okvaro ledvic (CrCl < 30 ml/min, ki niso na dializi) prilagajanje odmerka ni potrebno.
No dosage adjustment is required in patients with renal impairment (see sections 4.4 and 5.2).
Bolnikom z ledvično okvaro ni treba prilagajati odmerkov (glejte poglavji 4.4 in 5.2).
No dosage adjustment is required in patients with renal impairment.
Bolnikom z okvaro ledvic odmerka ni treba prilagoditi.
No dosage adjustment is required in patients with renal impairment.
Pri bolnikih z okvaro ledvic odmerka ni treba prilagajati.
No dosage adjustment is required on the basis of patient age or race (see sections 4.2 and 5.2).
Odmerkov ni treba prilagajati glede na bolnikovo starost ali raso (glejte poglavji 4.2 in 5.2).
No dosage adjustment necessary.
Odmerka ni treba prilagoditi.
No dosage adjustment necessary.
Prilagajanje odmerjanja ni potrebno.
No dosage adjustment of amlodipine/valsartan is required for patients with mild to moderate renal impairment (GFR >30 ml/min/1.73 m2).
Pri bolnikih z blago do zmerno okvaro ledvic (GFR >30 ml/min/1,73 m2) odmerka amlodipina/valsartana ni treba prilagajati.
No dosage adjustment of either medicinal product is recommended when anidulafungin is co-administered with ciclosporin, voriconazole or tacrolimus, and no dosage adjustment for anidulafungin is recommended when co-administered with amphotericin B or rifampicin.
Odmerjanja niti enega niti drugega zdravila ni treba prilagoditi, če je anidulafungin uporabljen sočasno s ciklosporinom, vorikonazolom ali takrolimusom; odmerjanja anidulafungina ni treba prilagoditi, če je uporabljen sočasno z amfotericinom B ali rifampicinom.
No dosage adjustment of entacapone is required for elderly patients.
Za starejše bolnike ni potrebno prilagajanje odmerjanja entakapona.
No dosage adjustment of entacapone is required for older people.
Za starejše ljudi ni potrebno prilagajanje odmerjanja entakapona.
No dosage adjustment of Galafold is required in patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter prilagoditev odmerka zdravila Galafold ni potrebna (glejte razdelek 5.2).
No dosage adjustment of Ifirmacombi is necessary in older people.
Pri starostnikih odmerka zdravila Ifirmacombi ni treba prilagajati.
No dosage adjustment of Imprida HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m2).
Pri bolnikih z blago do zmerno okvaro ledvic (hitrost glomerulne filtracije ≥30 ml/min/1,73 m2) odmerka zdravila Imprida HCT ni treba prilagajati.
No dosage adjustment of Irbesartan/Hydrochlorothiazide Teva is necessary in older people.
Pri starostnikih odmerka zdravila Irbesartan/hidroklorotiazid Teva ni treba prilagajati.
No dosage adjustment required for DUTREBIS or midazolam.
Odmerka zdravila DUTREBIS ali midazolama ni treba prilagoditi.
No dosage adjustment required for ISENTRESS or hormonal contraceptives (estrogen- and/or progesterone-based).
Odmerka zdravila ISENTRESS ali hormonskih kontraceptivov (estrogenskih in/ali progesteronskih) ni treba prilagajati.
No dosage adjustment required for ISENTRESS or midazolam.
Odmerka zdravila ISENTRESS ali midazolama ni treba prilagajati.
No dosage adjustment seems warranted for patients with moderate hepatic impairment based on limited data.
Na osnovi omejenih podatkov se zdi, da prilagajanje odmerkov pri bolnikih z zmerno jetrno okvaro ni utemeljeno.
No dosage adjustments are
Ni priporočil o prilagajanju
No dosage adjustments are necessary in patients with renal impairment based on study data in mild, moderate, and severe renal impairment and end stage renal disease (see sections 4.4 and 5.2).
Na podlagi podatkov študije, izvedene pri bolnikih z blago, zmerno in hudo ledvično okvaro ter pri bolnikih s končno ledvično odpovedjo, pri bolnikih z ledvično okvaro prilagajanje odmerka ni potrebno (glejte poglavji 4.4 in 5.2).
No dosage reduction is considered necessary but patients with hepatic impairment should initiate treatment with the lower starting dose, 3 g (3 tablets) per day (see section 5.1).
Zmanjšanje odmerka ni potrebno, vendar je treba pri bolnikih z okvaro jeter zdravljenje uvesti z manjšim začetnim odmerkom 3 g (3 tablete) na dan (glejte poglavje 5.1).
No dosage tapering is needed on treatment discontinuation.
Ob prekinitvi zdravljenja odmerka ni potrebno postopoma zmanjševati.
No dose
Pri
No dose adjustment
ni prilagoditve odmerka
No dose adjustment
Odmerka zdravila Victrelis
No dose adjustment
Prilagajanje odmerkov ni potrebno.
No dose adjustment
Prilagoditev odmerka
No dose adjustment
Prilagoditev odmerka efavirenza ni
No dose adjustment
Prilagoditev odmerka karisoprodola ni
No dose adjustment
Prilagoditev odmerka paracetamola ni
No dose adjustment (see section 5.2).
Odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment (see sections 4.4 and 5.2).
Odmerka ni treba prilagajati (glejte poglavji 4.4 in 5.2).
No dose adjustment for any of the medicinal products is necessary when either ketoconazole or itraconazole is administered in combination with amprenavir.
Pri sočasni uporabi ketokonazola ali itrakonazola in amprenavirja ni treba prilagajati odmerka pri nobenem zdravilu.
No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE.
Pri sočasni uporabi tovrstnih zdravil odmerka apiksabana ni treba prilagajati, vendar je treba pri bolnikih, ki prejemajo sočasno sistemsko zdravljenje z močnimi induktorji tako CYP3A4 kot P-gp, apiksaban za preprečevanje možganske kapi ter sistemske embolije pri bolnikih z NVAF in preprečevanje ponovne GVT ter PE uporabljati previdno.
No dose adjustment for apixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.
Pri sočasni uporabi manj močnih zaviralcev CYP3A4 in/ali P-gp odmerka apiksabana ni treba prilagajati.
No dose adjustment for concomitant use of paracetamol is required.
Pri sočasni uporabi odmerka paracetamola ni treba prilagajati.
No dose adjustment for concomitant use of paracetamol is required.
Prilagoditev odmerka sočasno uporabljenega paracetamola ni potrebna.
No dose adjustment for cyclobenzaprine required; increase dose if clinically indicated.
Prilagoditev odmerka ciklobenzaprina ni potrebna; povečajte odmerek, če je klinično indicirano.
No dose adjustment for either medicinal product is necessary when zidovudine is administered in combination with amprenavir.
Ob sočasni uporabi zidovudina in amprenavirja njunih odmerkov ni potrebno prilagajati.
No dose adjustment for EMEND is necessary for patients with renal impairment or for patients with ESRD undergoing haemodialysis.
Pri bolnikih z okvaro ledvic in pri bolnikih s končno odpovedjo ledvic na hemodializi odmerka zdravila EMEND ni treba prilagoditi.
No dose adjustment for INVEGA is recommended based on gender, race, or smoking status.
Prilagajanje odmerka zdravila INVEGA glede na spol, raso ali kajenje ni potrebno.
No dose adjustment for Viekirax with and without dasabuvir is recommended in HCV-infected patients with mild, moderate or severe renal impairment (see section 4.2).
Bolnikom, okuženim s HCV, ki imajo blago, zmerno ali hudo okvaro ledvic, odmerka zdravila Viekirax z dasabuvirjem ali brez njega ni treba prilagoditi (glejte poglavje 4.2).
No dose adjustment is
odmerka ni
No dose adjustment is
premljanje bolnikov (npr.
No dose adjustment is
Prilagajanje odmerkov ni
No dose adjustment is
Prilagajanje odmerkov ni potrebno.
No dose adjustment is
Prilagoditev
No dose adjustment is
Prilagoditev odmerka
No dose adjustment is
Prilagoditev odmerka pri
No dose adjustment is considered necessary for patients with mild hepatic impairment.
Pri osebah z blago okvaro jeter odmerka ni treba prilagajati.
No dose adjustment is considered necessary in patients with hepatic impairment.
Pri bolnikih z jetrno okvaro odmerka ni treba prilagajati.
No dose adjustment is considered necessary in patients with mild hepatic impairment.
Pri bolnikih z blago okvaro jeter odmerka ni treba prilagajati.
No dose adjustment is considered necessary in patients with renal impairment.
Pri bolnikih z ledvično okvaro odmerka ni treba prilagajati.
No dose adjustment is considered to be necessary (see section 5.2).
Ocenjuje se, da odmerka ni treba prilagajati (glejte poglavje 5.2).
No dose adjustment is necessary
Prilagoditev odmerka ni potrebna
No dose adjustment is necessary
Prilagoditev odmerka ni potrebna za nobeno od teh zdravil.
No dose adjustment is necessary (see section 5.2).
Prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
No dose adjustment is necessary (see section 5.2).
Prilagajanje odmerkov ni potrebno.
No dose adjustment is necessary (see section 5.2).
Prilagoditev odmerka ni potrebna (glej poglavje 5.2).
No dose adjustment is necessary according to gender.
Prilagoditev odmerka glede na spol ni potrebna.
No dose adjustment is necessary based on age (see section 5.2).
Prilagajanje odmerka na podlagi starosti ni potrebno (glejte poglavje 5.2).
No dose adjustment is necessary based on age.
Prilagoditev odmerka glede na starost ni potrebna.
No dose adjustment is necessary based on gender (see section 5.2).
Odmerka ni treba prilagoditi glede na spol (glejte poglavje 5.2).
No dose adjustment is necessary based on gender or race (see section 5.2).
Prilagoditev odmerka zaradi spola ali rase ni potrebna (glejte poglavje 5.2).
No dose adjustment is necessary based on gender.
Odmerka glede na spol bolnika ni potrebno prilagajati.
No dose adjustment is necessary based on race (see section 5.2).
Prilagajanje odmerkov glede na rasno pripadnost ni potrebno (glejte poglavje 5.2).
No dose adjustment is necessary for children 8-16 years.
Za otroke od 8 do 16 leta starosti prilagajanje odmerka ni potrebno.
No dose adjustment is necessary for concomitant use of amiodarone or quinidine (see sections 4.4, 4.5 and 5.2).
Odmerka ni treba prilagoditi za sočasno uporabo z amiodaronom ali kinidinom (glejte poglavja 4.4, 4.5 in 5.2).
No dose adjustment is necessary for efavirenz.
efavirenza ni potrebna.
No dose adjustment is necessary for efavirenz.
jemanjem efavirenza in
No dose adjustment is necessary for efavirenz.
Odmerka efavirenza ni treba prilagoditi.
No dose adjustment is necessary for efavirenz.
Prilagoditev odmerka efavirenza ni
No dose adjustment is necessary for efavirenz.
Prilagoditev odmerka ni potrebna
No dose adjustment is necessary for either medicinal product when abacavir is administered in combination with amprenavir.
Ob sočasni uporabi abakavirja in amprenavirja njunih odmerkov ni potrebno prilagajati.
No dose adjustment is necessary for either medicinal product when clarithromycin is administered in combination with amprenavir.
Ob sočasni uporabi klaritromicina in amprenavirja njunih odmerkov ni potrebno prilagajati.
No dose adjustment is necessary for either medicinal product when indinavir is administered in combination with amprenavir.
Ob sočasni uporabi indinavirja in amprenavirja njunih odmerkov ni potrebno prilagajati.
No dose adjustment is necessary for either medicinal product when lamivudine is administered in combination with amprenavir.
Ob sočasni uporabi lamivudina in amprenavirja njunih odmerkov ni potrebno prilagajati.
No dose adjustment is necessary for either medicinal product when saquinavir is administered in combination with amprenavir.
Ob sočasni uporabi sakvinavirja in amprenavirja njunih odmerkov ni potrebno prilagajati.
No dose adjustment is necessary for either medicinal product.
Prilagoditev odmerka ni potrebna za nobeno od teh zdravil.
No dose adjustment is necessary for either medicinal product.
za nobeno od teh zdravil.
No dose adjustment is necessary for either medicinal product.
za nobeno od zdravil.
No dose adjustment is necessary for elderly patients.
Pri starejših bolnikih odmerka ni treba prilagoditi.
No dose adjustment is necessary for escitalopram.
Prilagoditev odmerka ni potrebna za escitalopram.
No dose adjustment is necessary for older people (see section 5.1 and 5.2).
Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavji 5.1 in 5.2).
No dose adjustment is necessary for patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter odmerka ni potrebno prilagajati (glejte poglavje 5.2).
No dose adjustment is necessary for patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
No dose adjustment is necessary for patients with mild hepatic impairment (Child-Pugh Class A).
Zato pri bolnikih z blago okvaro jeter prilagajanje odmerka ni potrebno.
No dose adjustment is necessary for patients with mild or moderate renal impairment (CLcr equal or greater than 30 ml/min), as shown in study BM 16549 where the majority of patients had mild to moderate renal impairment.
Za bolnike z blago ali zmerno okvaro ledvic (očistek kreatinina (CLcr) enak ali večji kot 30 ml/min) prilagajanje odmerkov ni potrebno, kar se je pokazalo v študiji BM 16549, kjer je večina bolnikov imela blago do zmerno okvaro ledvic.
No dose adjustment is necessary for patients with mild or moderate renal impairment where creatinine clearance is equal or greater than 30 ml/min.
Bolnikom z blago do zmerno okvaro ledvic, ki imajo očistek kreatinina vsaj 30 ml/min, ni treba prilagoditi odmerka.
No dose adjustment is necessary for patients with mild or moderate renal impairment where serum creatinine is equal or below 200 µmol/l (2.3 mg/dl) or where creatinine clearance (measured or estimated) is equal or greater than 30 ml/min.
Pri bolnikih z blago do zmerno ledvično okvaro, ki imajo serumski kreatinin enak ali manjši kot 200 µmol/l (2,3 mg/dl) ali očistek kreatinina (izmerjen ali ocenjen) enak ali večji kot 30 ml/min, prilagajanje odmerkov ni potrebno.
No dose adjustment is necessary for patients with mild renal impairment (CLcr ≥50 and <80 mL/min).
Pri bolnikih z blago ledvično okvaro (CLcr ≥ 50 in < 80 ml/min) prilagajanje odmerka ni potrebno.
No dose adjustment is necessary for patients with mild renal impairment (CLcr ≥50 and <80 mL/min).
Pri bolnikih z blago ledvično okvaro (CLcr ≥ 50 in < 80 ml/min) prilagajanje odmerkov ni potrebno.
No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
Pri bolnicah z blago do zmerno jetrno okvaro odmerka ni treba prilagajati.
No dose adjustment is necessary for patients with mild, moderate or severe hepatic impairment (Child- Pugh Class A, B or C, respectively).
Bolnikom z blago (Child-Pugh A), zmerno (Child-Pugh B) ali hudo (Child-Pugh C) okvaro jeter odmerka ni treba prilagoditi.
No dose adjustment is necessary for patients with pre-existing mild hepatic impairment, Child-Pugh Class A.
Bolnikom z blago okvaro jeter Child-Pugh razreda A ni treba prilagajati odmerkov.
No dose adjustment is necessary for patients with renal impairment.
Pri bolnikih z motnjami v delovanju ledvic prilagoditev odmerka ni potrebna.
No dose adjustment is necessary for raltegravir.
(indukcija UGT1A1)
No dose adjustment is necessary for raltegravir.
odmerkom so se pri sočasni
No dose adjustment is necessary for the elderly based on age alone (see section 5.2).
Prilagoditev odmerka pri starejših bolnikih zgolj zaradi starosti ni potrebna (glejte poglavje 5.2).
No dose adjustment is necessary for the elderly.
Odmerka pri starejših ni potrebno prilagoditi.
No dose adjustment is necessary for the elderly.
Pri starejših ni potrebna prilagoditev odmerkov.
No dose adjustment is necessary for the older people.
Prilagajanje odmerkov pri starejših bolnikih ni potrebno.
No dose adjustment is necessary for the paediatric population.
Prilagajanje odmerka za pediatrično populacijo ni potrebno.
No dose adjustment is necessary for the paediatric population.
Za pediatrično populacijo ni potrebno prilagajanje odmerka
No dose adjustment is necessary for these sub- populations.
Pri teh populacijah prilagajanje odmerka ni potrebno.
No dose adjustment is necessary for zolpidem.
Prilagoditev odmerka
No dose adjustment is necessary for zolpidem.
Prilagoditev odmerka ni potrebna za zolpidem.
No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function.
Pri starejših bolnikih in bolnikih z okvaro delovanja ledvic ali jeter odmerka ni treba prilagajati.
No dose adjustment is necessary in elderly patients, except in cases of moderate to severe renal insufficiency (see section 4.2).
Pri starostnikih prilagoditev odmerka ni potrebna, razen v primeru zmerne do hude ledvične insuficience (glejte poglavje 4.2).
No dose adjustment is necessary in elderly patients.
Pri starejših bolnikih prilagajanje odmerka ni potrebno.
No dose adjustment is necessary in elderly patients.
Starejšim bolnikom odmerka ni treba prilagoditi.
No dose adjustment is necessary in patients 65 years and older (see section 5.2).
Pri bolnikih, ki so stari 65 let ali več, odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dose adjustment is necessary in patients with hepatic impairment (see section 5.2).
Pri bolnikih z okvaro jeter prilagajanje odmerkov ni potrebno (glejte poglavje 5.2).
No dose adjustment is necessary in patients with hepatic impairment (see section 5.2).
Prilagoditev odmerka pri bolnikih z okvaro jeter ni potrebna (glejte poglavje 5.2).